Frankfurt - Delayed Quote EUR

InnoCan Pharma Corporation (IP4.F)

0.1960

+0.0150

(+8.29%)

As of 3:57 PM GMT+2. Market Open.

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.

CNW Group 18 hours ago
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2023.

CNW Group 21 days ago
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the signing of an agreement with the Hebrew University, which facilitate Innocan to initiate the Food and Drug Administration (FDA) approval process for its liposome CBD platform (LPT-CBD) in accordance with FDA's Chemistry Manufacturing Control (CDC) Guidelin

CNW Group 28 days ago
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million

Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 7,952,840 Units at a price of $0.25 per Unit (the "Offering Price") for aggregate gross proceeds of $1,988,210.

CNW Group last month
Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the following:

CNW Group last month
Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company's pharmacokinetic study of its LPT-CBD platform in rabbits.

CNW Group last month
Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), is pleased to announce that CEO Iris Bincovich will be a speaker at the White Label World Expo in London on February 27th and 28th. She will be speaking about the "The Magic of Proven Science in CBD Products" along with leading speakers from Alibaba, Google, LinkedIn, TikTok and other sourcing professionals, retail prediction experts and industry-defining leaders who will give you their take on 2024's ho

CNW Group 2 months ago
Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), is pleased to provide the following corporate update:

CNW Group 2 months ago
Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the "Company" or "Innocan"), is pleased to announce that it will provide a corporate update to the investment community and its shareholders through a Zoom livestream on February 12, 2024, at 4:00pm EST.

CNW Group 2 months ago
Innocan Pharma Announces Expert Team for LPT CBD Application to United States Food and Drug Administration

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce establishment of a specialized team to prepare the Company's submission to the United States Food and Drug Administration (the "FDA") for the human application of its LPT CBD platform.

CNW Group 4 months ago
Innocan Pharma Reports Q3 2023 Results Including US$3.334M Increase in Revenues Compared to Q3, 2022

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property portfolio, is pleased to announce its financial results for the three and nine months period ended September 30, 2023.

CNW Group 4 months ago
Innocan Pharma Announces Promising LPT-CBD Safety Indications -Implications from a prolong use in animals

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the company's latest groundbreaking findings.

CNW Group 5 months ago
Innocan Pharma reports a groundbreaking discovery regarding its LPD platform and global CBD research

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the company's latest groundbreaking findings. Research over the past several months has identified animals that metabolize cannabidiol (CBD), administered as a liposomal CBD injection, in a manner similar to humans. This means that results related to LPT-CBD metabolism obtained from experiments with these types of anim

CNW Group 5 months ago
Innocan Pharma Announces Closing of Second and Final Tranche of Financing

Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed the second and final tranche (the "Second Tranche") of its previously announced private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 4,005,408 Units at a price of $0.30 per Unit (the "Offering Price") for aggregate gross proceeds of $1,201,622.40. In total, the Company issued an aggregate of 5,42

CNW Group 5 months ago
Innocan Pharma Announces Closing of First Tranche Private Placement and Provides Corporate Update

Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed the first of two tranches (the "First Tranche") of its previously announced private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 1,420,200 Units at a price of $0.30 per Unit (the "Offering Price") for aggregate gross proceeds of $426,060. The Company expects to complete a second and final tranche of the Offer

CNW Group 6 months ago
Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million

NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HERZLIYA, Israel and CALGARY, Alberta, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Innocan Pharma Corporation (the “Company”) (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has entered into an agreement with Research Capital Corporation as the sole agent and sole bookrunner (the “Agent”) on a “best efforts” agency basis in connection with a marketed private placement offering (the “Offer

GlobeNewswire 6 months ago
Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory Board

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pioneering pharmaceutical technology company specializing in innovative wellness products, is elated to announce the appointment of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Scientific Advisory Board (SAB). Dr. Pergolizzi, a distinguished expert in the field of pain management and critical care medicine, will be instrumental in the Company's upcoming planned FDA filing for human medications.

CNW Group 7 months ago
Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its hair care cream (the "Product").

CNW Group 7 months ago
Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD Injection

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the results of a clinical study regarding the pain-relieving effects and safety of the Company's subcutaneous liposomal CBD (Innocan's LPT platform) for dogs with osteoarthritis. Published in the Frontiers in Veterinary Science Journal, under the research topic "Use of Cannabis Derivatives in Veterinary Medicine" (the "Study"). The Study highlights that CBD plasma levels were dete

CNW Group 7 months ago
Innocan Pharma Reports Q2 2023 Results Including US$2.706M Increase in Revenues Compared to Q2, 2022

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property portfolio, is pleased to announce its financial results for the three and six months period ended June 30, 2023.

CNW Group 7 months ago

Performance Overview

Return	IP4.F	S&P/TSX Composite index
YTD	+0.41%	+4.93%
1-Year	+35.92%	+6.27%
3-Year	-38.75%	+15.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

InnoCan Pharma Corporation (IP4.F)

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M

Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.

Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million

Innocan Pharma's LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study

Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits

Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024

Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights

Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST

Innocan Pharma Announces Expert Team for LPT CBD Application to United States Food and Drug Administration

Innocan Pharma Reports Q3 2023 Results Including US$3.334M Increase in Revenues Compared to Q3, 2022

Innocan Pharma Announces Promising LPT-CBD Safety Indications -Implications from a prolong use in animals

Innocan Pharma reports a groundbreaking discovery regarding its LPD platform and global CBD research

Innocan Pharma Announces Closing of Second and Final Tranche of Financing

Innocan Pharma Announces Closing of First Tranche Private Placement and Provides Corporate Update

Innocan Pharma Announces Brokered LIFE Offering of Units for Up to $3 Million

Innocan Pharma Announces the Addition of Dr. Joseph V. Pergolizzi, Jr., M.D. to its Advisory Board

Innocan Pharma Announces Promising Results from Hair Care Cream Efficacy Test

Innocan Pharma Announces Clinical Study Results: Evidence of Reduced Osteoarthritis Pain in Dogs After Liposomal CBD Injection

Innocan Pharma Reports Q2 2023 Results Including US$2.706M Increase in Revenues Compared to Q2, 2022

Performance Overview